Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_4
3
33%
Ph phase_1
3
33%
Ph not_applicable
2
22%
Ph phase_3
1
11%

Phase Distribution

3

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(4)

Detailed Status

Completed5
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (33.3%)
Phase 31 (11.1%)
Phase 43 (33.3%)
N/A2 (22.2%)

Trials by Status

terminated333%
withdrawn111%
completed556%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9